These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18020905)

  • 21. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harvard turns to matchmaking to speed translational research.
    Wadman M
    Nat Med; 2008 Jul; 14(7):697. PubMed ID: 18607352
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase 0 trials speed early drug development.
    McBride D
    ONS Connect; 2007 Sep; 22(9):21. PubMed ID: 17910234
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Burczynski ME
    Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Biomarkers Forum--Harnessing the Potential of Biomarkers from Translational Research, throughout Clinical Trials. 13-14 September 2007, Prague, Czech Republic.
    Guergova-Kuras M
    IDrugs; 2007 Nov; 10(11):782-3. PubMed ID: 17968758
    [No Abstract]   [Full Text] [Related]  

  • 26. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.
    Bowsher RR; Sailstad JM
    J Pharm Biomed Anal; 2008 Dec; 48(5):1282-9. PubMed ID: 18977625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers in translation; past, present and future.
    Lock EA; Bonventre JV
    Toxicology; 2008 Mar; 245(3):163-6. PubMed ID: 18272278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partnership between academia and industry for drug discovery in Alzheimer's disease.
    Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
    Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
    Muller PY; Dieterle F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hands-on molecular imaging: real-time visualization tools bridge gaps in translational medicine.
    Vanderheyden JL
    IDrugs; 2008 Aug; 11(8):579-83. PubMed ID: 18683093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives.
    Cummings JL
    Alzheimers Dement; 2009 Mar; 5(2):108-13. PubMed ID: 19328437
    [No Abstract]   [Full Text] [Related]  

  • 33. Using controlled clinical trials to learn more about acute drug-induced liver injury.
    Watkins PB; Seligman PJ; Pears JS; Avigan MI; Senior JR
    Hepatology; 2008 Nov; 48(5):1680-9. PubMed ID: 18853438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bias in the design, interpretation, and publication of industry-sponsored clinical research.
    Hammerschmidt D
    Minn Med; 2008 Jun; 91(6):46-7. PubMed ID: 18616022
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronicles in drug discovery.
    Cole P; Vasiliou S
    Drug News Perspect; 2010 Mar; 23(2):138-42. PubMed ID: 20369079
    [No Abstract]   [Full Text] [Related]  

  • 36. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease.
    Bohanna I; Georgiou-Karistianis N; Hannan AJ; Egan GF
    Brain Res Rev; 2008 Jun; 58(1):209-25. PubMed ID: 18486229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF biomarkers: pinpointing Alzheimer pathogenesis.
    Mattsson N; Blennow K; Zetterberg H
    Ann N Y Acad Sci; 2009 Oct; 1180():28-35. PubMed ID: 19906258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer biomarkers: current issues and future directions.
    Jain KK
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.